In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MeMed’s Mission: Pressing Its Fingerprint Against AMR

Executive Summary

Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.

You may also be interested in...



MeMed Secures $93M Financing To Commercialize Diagnostics Platform

The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.

Point Of Care Diagnostics In 2022: New Technology But Old Problems

Following a busy year for point of care diagnostics, the industry is facing a period of consolidation. The drive for new technologies is being countered by regulatory and financial issues.

Muvon Therapeutics: The Road To Expansion

Deana Mohr, Muvon Therapeutics’ co-founder and chief executive, and one of In Vivo’s 2022 Rising Leaders, aspires to push the organization to the next level by scaling up the company and developing its therapies into marketable products.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel